One Quality Standard

One Quality Standard

Our mission is to provide 7 billion people access to high quality medicine. But access is about more than stocking pharmacy shelves.

Why so passionate about policy?
Because we believe in breaking down the barriers between safe, effective and affordable medicines and the people all over the world who need them.

Policies We Support

Promoting One Quality Standard
U.S. legislation, including the Food and Drug Administration Safety and Innovation Act and the Generic Drug User Fee Amendments, expand the global reach of the Food and Drug Administration and ensure regular inspection of, and high quality standards for, all manufacturing facilities that supply the U.S. pharmaceutical market.

Increasing Generic Utilisation
In the U.S. generic utilisation saved more than $1 trillion from 2002 to 2011. In countries where utilisation is low, we’re educating governments about the role of generics in providing affordable health care and access to medicine.

Driving Biogeneric Access
Biogenerics are generic equivalents of biologics—expensive medicines for diseases like multiple sclerosis, rheumatoid arthritis, diabetes and cancer. We promote effective biogeneric approval pathways that drive interchangeability, maximise patient access to more affordable, high quality biologics and reduce health care spending.

Raising Anaphylaxis Awareness
Food allergy is the most common cause of anaphylaxis, a life-threatening allergic reaction that demands immediate treatment with adrenaline. It's estimated in Ireland that approximately 5pc of children and 3pc of adults suffer from a food allergy. We advocate for policy that expands access to adrenaline auto-injectors to entities such as schools.

Mylan Ireland is the first company in Europe to install anaphylaxis stations into our office and plants.

Stemming HIV/AIDS
Approximately 34 million people in the developing world are infected with HIV, the virus that causes AIDS. Twenty-six million need treatment. Less than a quarter of them receive it. We advocate for funding to focus on proven methods of treatment and prevention.

Last Updated  27/02/2015